DNLI News and Press, Denali Therapeutics Inc. From 01/28/20

Denali Therapeutics (NASDAQ: DNLI ) intends to offer $150M shares of its common stock in a public offering. More news on: Denali Therapeutics Inc., Healthcare stocks news, , Read more ...

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $150 million of shares of its common stock. In addition, Denali Therapeut...

Relmada Therapeutics (NASDAQ: RLMD ) initiated with Buy rating and $75 (73% upside) price target at Jefferies. More news on: Relmada Therapeutics, Inc., Biogen Inc., Denali Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Shares of Denali Therapeutics (NASDAQ: DNLI) , a biopharmaceutical company focused on neurodegenerative diseases , rose 24% as of 2:36 p.m. EST on Tuesday in response to announcing that its pipeline is progressing. Here are the key takeaways for investors: Image source: Getty Images. Con...

Denali Therapeutics ( DNLI +17.5% ) announces positive early-stage data on lead candidate DNL201 in Parkinson's disease (PD) as part of its pipeline update. Highlights: More news on: Denali Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...

LRRK2 inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinson’s disease  LRRK2 inhibitor DNL151 Phase 1 demonstrated high levels of target and pathway engagement and modulation o...

There might be something in our brains -- some fear of the unknown -- that keeps us from buying a stock at its all-time high. When you buy at the high, you have to realize that all the other holders of the stock got a better price than you did. You're in last place with the highest cost basis. S...

CAMBRIDGE, Mass. , Dec. 19, 2019 /PRNewswire/ --   Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based...

The Alzheimer's community got a boost at the end of October when Biogen (NASDAQ: BIIB) announced it would file for approval from the U.S. Food and Drug Administration for aducanumab, its Alzheimer's disease drug. This caught patients and investors off guard since Biogen scrapped the pro...

Denali Therapeutics (NASDAQ: DNLI ): Q3 GAAP EPS of -$0.48 beats by $0.09 . More news on: Denali Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...